KIYATEC is ushering in a new world of cancer diagnostics that
use living cells grown and tested in a more relevant 3D environment.

Clinical Cancer Diagnostics

Cancer DiagnosticsKIYATEC is driving the future of clinical cancer diagnostics to provide more accurate prediction of patient-specific response to cancer treatments.  Placing the patient's own living cancer cells into a more biologically relevant 3D culture environment, KIYATEC cell-based assays can better assist oncologists with improved response data and faster turnaround!

Read More

Services & Partnering

3D Cell CultureKIYATEC’s 3D cell-based models provide physiologically-relevant, efficient and cost-effective platforms for testing both small molecule and biologic drugs in an in vivo-like environment to better understand drug efficacy, response or resistance. Opportunities also exist for co-clinical trial partnering to apply ex vivo patient selection based on our Drug Response Profiling (DRP) approach.
Read More


AACR 2015: Three KIYATEC Abstracts Accepted for Poster Presentations
Read More

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics
Read More

KIYATEC hires Bryce Chaney as Sr Director of Business Development
Read More

KIYATEC awarded AdvaMed Emerging Growth Company presentation and scholarship
Read More



AACR 2015
Philadelphia, PA
Apr 18-22


ASCO 2015
Chicago, IL
May 29 - Jun 2


World Preclinical Congress 2015
Boston, MA
Jun 10-12